We focused on patients who received frontline treatment for CML-MBP in order to minimize the variability associated with including patients within the same analysis who had no prior BP treatment with those who had relapsed/refractory disease to one or more prior BP regimens. The gene discussed is MBP; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.